Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
Clinical trial NCT05822752 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05822752
- Sponsor
- AbbVie
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-21
- Primary completion
- 2026-11-01
- Enrollment
- 130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.